Finding into death of Richard John Norton
Deceased
Richard John Norton
Demographics
75y, male
Date of death
2025-03-30
Finding date
2026-10-28
Cause of death
Complications of an out of hospital cardiac arrest secondary to anaphylaxis triggered by peptide injection; asthma and hypertrophic cardiomyopathy as contributing factors
AI-generated summary
A 75-year-old man died from anaphylaxis triggered by self-administered peptide injections (CJC1295/Ipamorelin), which he was taking in excess of the prescribed dose. He injected a dose at home on 28 March 2025, collapsed with cardiac arrest, and died two days later at The Alfred Hospital. Critical clinical lessons: (1) unapproved peptide therapies lack evidence of safety and efficacy; (2) the prescriber failed to directly contact the patient to assess for misuse and overdosing before authorizing a replacement prescription on 28 March; (3) inadequate clinical record-keeping meant red flags were not captured; (4) the patient had been experiencing anaphylaxis symptoms (flushing, chest tightness, shortness of breath) for days before the fatal collapse, but escalation and appropriate counselling did not occur. The medical board found the prescriber's care at a reasonable standard but determined his record-keeping was sparse and inadequate, and direct risk assessment before re-prescribing was not undertaken.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes.
Error types
Drugs involved
Clinical conditions
Contributing factors
- Anaphylaxis from peptide injection
- Patient self-administration of double the prescribed dose
- Asthma exacerbating airway involvement in anaphylaxis
- Hypertrophic cardiomyopathy increasing risk of lethal arrhythmias
- Prescriber failure to directly assess patient before re-prescribing despite known over-dosing
- Inadequate clinical record-keeping preventing identification of red flags
Coroner's recommendations
- The Therapeutic Goods Administration should review the therapeutic benefits and safety risks of peptides such as CJC1295/Ipamorelin and consider whether further restrictions ought to be imposed on their use, such as classification under Schedule 10 of the Therapeutic Goods (Poisons Standard) Instrument 2026 (Cth), to ban use for human purposes subject to specific exceptions such as clinical trials or other experimental use.
Full text
Related cases
Source and disclaimer
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. All court orders for redaction and non-publication are respected; where a court PDF has technically defective redaction, the hidden text is removed from our archived copy and the full text is withheld. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction —